The Federal Trade Commission accuses OptumRx, UnitedHealthcare's pharmacy benefit manager, of massively inflating costs on numerous specialty generic drugs, marking them up thousands of percent.
The 'Big 3 PBMs', including OptumRx, increased prices on 22 percent of all analyzed specialty medications, profiting hundreds of millions at the expense of patients.
OptumRx's markups led to out-of-pocket costs for drugs like abiraterone soaring between $1,379 to $13,274 per year, significantly burdening cancer patients.
The FTC report highlighting significant price gouging comes shortly after the murder of UHC CEO Brian Thompson, raising questions about healthcare experiences ingrained in patient struggles.
#pharmacy-benefit-managers #drug-pricing #healthcare-costs #federal-trade-commission #unitedhealthcare
Collection
[
|
...
]